Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-09-01 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing the publication of clinical trial results in a scientific journal. It details the findings of the Phase II CESTO II trial for their drug candidate NFL-101. Since this is a general corporate announcement regarding operational/scientific progress rather than a formal financial report, a regulatory filing, or a specific investor presentation, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-09-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing a new scientific collaboration with McLean Hospital to study the mechanism of action of their drug candidate, NFL-101. It provides details on the research scope, the strategic importance of the partnership, and quotes from leadership. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a simple report publication announcement. As it is a general corporate announcement regarding business development and research activities, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-07-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by NFL Biosciences announcing a new scientific collaboration with McLean Hospital to study the mechanism of action of their drug candidate, NFL-101. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business development and research activities, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-07-28 English
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the company has secured €1.2 million in non-dilutive financing (bank loans and a repayable advance). This falls under the category of company fundraising and financing activities. It is not a report publication announcement, nor is it a capital change (like a share issue), but rather a financing update.
2025-07-22 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 100% confidence The document is a press release announcing that the company has secured 1.2 million euros in non-dilutive financing through a combination of government innovation grants and bank loans. This falls under the category of company fundraising and financing activities. It is not a report publication announcement, but rather a direct announcement of a capital/financing event.
2025-07-22 French
NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoki
Board/Management Information Classification · 100% confidence The document is a press release announcing the expansion of Dr. Yannick Plétan's role as Chief Medical Officer at NFL Biosciences. This constitutes a change in senior management/leadership. According to the provided definitions, announcements regarding changes in senior management fall under the 'Board/Management Information' (MANG) category.
2025-07-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.